News

The Charcot-Marie-Tooth Association (CMTA), the national patient advocacy organization leading CMT research, today announced the appointment of David Coldiron to its Board of Directors.

As you’ll learn from watching this video by two young members of our CMT family, tiredness, exhaustion, fatigue and “sluggishness” are all part of having CMT.

Bruce Chizen, a special advisor to the Board of Directors, will match donations to CMT2 research on a one-to-one basis, up to $500,000.

The Type 2 Issue: We have set the stage for a number of Type 2 breakthroughs on our way to treatments for CMT.

The CMTA today announced another $335,000 in grants to top CMT scientists leading the field in CMT Type 1 research. The grants cover work on types 1A, 1B and 1X and other demyelinating forms of CMT, including type 4.